dicycloverine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
spasmolytics with a papaverine-like action 868 77-19-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dicymine
  • dicycloverine hydrochloride
  • dicycloverine
  • dicyclomine
  • dicycloverin
  • dicyclomine hydrochloride
  • dicyclomine HCl
A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.
  • Molecular weight: 309.49
  • Formula: C19H35NO2
  • CLOGP: 6.14
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 29.54
  • ALOGS: -4.98
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O
80 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.30 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
May 11, 1950 FDA FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 215.40 35.93 58 164 46585 2311278
Completed suicide 158.38 35.93 39 183 20995 2336868
Toxicity to various agents 70.40 35.93 23 199 32731 2325132
Incorrect route of product administration 60.84 35.93 14 208 5322 2352541
Neuroleptic malignant syndrome 49.40 35.93 10 212 2070 2355793
Hypothermia 49.08 35.93 10 212 2138 2355725
Medication error 38.64 35.93 10 212 6121 2351742
Overdose 38.57 35.93 13 209 19894 2337969
Constipation 37.51 35.93 13 209 21616 2336247

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 64.92 44.49 19 73 29122 1717567
Completed suicide 60.85 44.49 16 76 16296 1730393

Pharmacologic Action:

SourceCodeDescription
ATC A03AA07 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Synthetic anticholinergics, esters with tertiary amino group
CHEBI has role CHEBI:48876 muscarinic antagonist
CHEBI has role CHEBI:53784 antispasmodic drug
CHEBI has role CHEBI:50370 parasympatholytic
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents
FDA EPC N0000175574 Anticholinergic

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Irritable bowel syndrome indication 10743008 DOID:9778
Brain damage contraindication 2470005
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Hepatic encephalopathy contraindication 13920009 DOID:13413
Severe chronic ulcerative colitis contraindication 14311001
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Poisoning by phenobarbital contraindication 64921004
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Gastrointestinal obstruction contraindication 126765001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Fever greater than 100.4 Fahrenheit contraindication 426000000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.41 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 9.03 DRUG MATRIX CHEMBL
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9.08 DRUG MATRIX CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 4.77 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 7.16 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.08 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.61 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.85 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.39 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.80 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 9.39 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 8.77 DRUG MATRIX
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.55 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 6.60 IUPHAR
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 8.69 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor IC50 6.33 DRUG MATRIX
SMR1-alpha2 Unclassified Ki 6.54 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 8.61 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 7.33 CHEMBL

External reference:

IDSource
D004025 MESH_DESCRIPTOR_UI
4017870 VUID
N0000179550 NUI
C0591771 UMLSCUI
D00717 KEGG_DRUG
4KV4X8IF6V UNII
619 INN_ID
41493007 SNOMEDCT_US
372732007 SNOMEDCT_US
3361 RXNORM
d00999 MMSL
4019716 VANDF
004711 NDDF
67-92-5 SECONDARY_CAS_RN
CHEMBL1123 ChEMBL_ID
DB00804 DRUGBANK_ID
CHEMBL1200479 ChEMBL_ID
CHEBI:4514 CHEBI
355 IUPHAR_LIGAND_ID
3042 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 0143-1227 TABLET 20 mg ORAL ANDA 17 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-3126 CAPSULE 10 mg ORAL ANDA 17 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1610 CAPSULE 10 mg ORAL ANDA 17 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1620 TABLET 20 mg ORAL ANDA 17 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-7384 CAPSULE 10 mg ORAL ANDA 17 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-1980 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 16 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-0586 CAPSULE 10 mg ORAL ANDA 17 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1282 TABLET 20 mg ORAL ANDA 17 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0794 CAPSULE 10 mg ORAL ANDA 16 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0795 TABLET 20 mg ORAL ANDA 16 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-1161 SOLUTION 10 mg ORAL ANDA 15 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 0615-0327 CAPSULE 10 mg ORAL ANDA 13 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7754 CAPSULE 10 mg ORAL ANDA 16 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7755 TABLET 20 mg ORAL ANDA 16 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-6173 INJECTION 10 mg INTRAMUSCULAR ANDA 16 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6969 CAPSULE 10 mg ORAL ANDA 17 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6987 CAPSULE 10 mg ORAL ANDA 17 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6988 TABLET 20 mg ORAL ANDA 17 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-520 CAPSULE 10 mg ORAL ANDA 16 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-560 TABLET 20 mg ORAL ANDA 17 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 10544-597 TABLET 20 mg ORAL ANDA 9 sections
Dicyclomine HCl HUMAN PRESCRIPTION DRUG LABEL 1 14789-010 INJECTION 10 mg INTRAMUSCULAR ANDA 16 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16590-077 CAPSULE 10 mg ORAL ANDA 11 sections
DICYCLOMINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-324 TABLET 20 mg ORAL ANDA 8 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 17478-015 INJECTION 20 mg INTRAMUSCULAR ANDA 16 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-1161 SOLUTION 10 mg ORAL ANDA 12 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 21695-218 CAPSULE 10 mg ORAL ANDA 12 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-219 TABLET 20 mg ORAL ANDA 13 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24201-585 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 16 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 31722-963 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 17 sections